A collaboration for cosmetic ingredient screening
Syntivia and NeoVirTech announce a collaboration for high-content and high-quality cosmetic active ingredient screening. The synergy between knowledge in the dermo-cosmetic field and know-how in high content imaging paves the way for next generation screening for the discovery of tomorrow’s block buster products.
NeoVirTech, an award winning innovative French company focusing its activity on antiviral discovery and virus imaging, recently acquired a Thermo Scientific CellInsight CX7 high content screening microscope. This integrated performant system allows for high quality in screening and analysis, rapid discovery of active compounds with highly reliable quantification and very high-definition imaging.
The CellInsight CX7 High-Content Screening Platform offers a wide choice of imaging modes to extract information from biological samples. The entire fluorescent spectrum can be used to optimize assays, and either widefield or confocal optics are available for any channel. This microscope also offers 4-color brightfield options for colorimetric analysis of tissue sections.
NeoVirTech provides its equipment and screening expertise in this collaboration for cosmetic active ingredients screening.
On the other hand, Syntivia provides its cellular models and biology expertise in cosmetic science. All skin cell types, alive or fixed, can be processed and analysed. Keratinocytes, fibroblasts, melanocytes, adipocytes, sebocytes, neural cells and more can be treated and analysed with your cosmetic compound under a wide range of conditions.
NeoVirTech’s screening expertise combined with Syntivia’s cellular culture and labelling techniques allows to obtain large amounts of reliable data, 2D high quality imaging precise quantification of visible or fluorescent markers to detect the activity of various cosmetic compounds on skin cells.
“We are delighted to start a collaboration with Syntivia, one of the experts in the discovery and development of dermo-cosmetic compounds. This collaboration will extend and diversify our screening activities, maximise our screening platform and provide rapid quantitative and high-quality data to our partners.” – Franck Gallardo, PhD, CEO and Founder of NeoVirTech.
Don’t hesitate to contact us for more information on cosmetic ingredient screening.